Trimegavog 1 Tablet SR
Manufacturer
Aristo Pharmaceuticals Pvt Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Key Information
Short Description
Trimegavog 1 Tablet SR is a combination of anti-diabetic drugs used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels.
Dosage Form
Tablet SR
Introduction
Trimegavog 1 Tablet SR is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Trimegavog 1 Tablet SR is to be taken empty stomach.
Safety Information
Side Effects
No common side effects listed.
Alcohol Warning
It is unsafe to consume alcohol with Trimegavog 1 Tablet SR.
Breastfeeding Warning
Trimegavog 1 Tablet SR is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Pregnancy Warning
Trimegavog 1 Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
How it works
Trimegavog 1 Tablet SR is a combination of three antidiabetic medicines:
Quick Tips
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal. Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
Related Medicines
Glimisave MV 1 Tablet
Voglinorm-GM1 Tablet
Glucoryl-MV1 Tablet
Voglimac GM 1 Tablet SR
Vogs-GM 1 Tablet
Vogli-GM 1 Tablet
Zoryl-MV 1 Tablet
Glimy M V1 Tablet
Amaryl MV 1mg Tablet
Tribetrol 1 Tablet
Frequently asked questions
What is Trimegavog 1 Tablet SR?
Trimegavog 1 Tablet SR contains Glimepiride, Metformin, and Voglibose. It's used to manage type 2 diabetes mellitus (DM). The medicines work together to improve blood glucose levels when taken with a healthy diet and exercise regimen.
What are the possible side effects of Trimegavog 1 Tablet SR?
Common side effects include hypoglycemia (low blood sugar), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection. It's important to note that this medicine is not for treating type 1 diabetes.
Are there any specific conditions in which Trimegavog 1 Tablet SR should not be taken?
This medication should be avoided by individuals with known allergies to the components or excipients of this medicine. It's also contraindicated for patients with moderate to severe kidney disease, inflammatory bowel disease (IBD), colonic ulcerations, and underlying metabolic acidosis including diabetic ketoacidosis.
Is it safe to take alcohol while I am also taking Trimegavog 1 Tablet SR?
No, it's not recommended to consume alcohol when taking Trimegavog 1 Tablet SR. It can lower blood sugar levels (hypoglycemia) and increase the risk of lactic acidosis.
Can the use of Trimegavog 1 Tablet SR cause hypoglycemia?
Yes, using Trimegavog 1 Tablet SR can lead to hypoglycemia. If symptoms appear such as nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky, it's crucial to monitor blood sugar levels regularly. It is vital to keep glucose tablets, honey, or fruit juice readily accessible.
What are the instructions for the storage and disposal of Trimegavog 1 Tablet SR?
Store this medicine in its original packet or container, tightly sealed. It should be stored according to the instructions on the packaging label. Dispose of unused medicine responsibly, ensuring it's not consumed by pets, children, or others.
